REPLICEL LIFE SCIENCES INC.

(REPCF)
Delayed OTC Markets  -  05/13 10:18:29 am EDT
0.0952 USD   -4.80%
03/29REPLICEL LIFE SCIENCES : 51-102F3 MATERIAL CHANGE REPORT - Form 6-K
PU
03/29REPLICEL LIFE SCIENCES : New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key markets - Form 6-K
PU
03/22RepliCel Announces Non-brokered Private Placement
AQ
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

RepliCel Life Sciences Inc. announced that it has received CAD 0.99892 million in funding from MainPointe Pharmaceuticals, LLC

12/20/2021 EDT

On December 20, 2021, RepliCel Life Sciences Inc. closed the transaction. The company issued 1,479,882 common shares at a price of CAD 0.675 per share. The transaction included participation from MainPointe Pharmaceuticals, LLC.


ę S&P Capital IQ 2021
All news about REPLICEL LIFE SCIENCES INC.
03/29REPLICEL LIFE SCIENCES : 51-102F3 MATERIAL CHANGE REPORT - Form 6-K
PU
03/29REPLICEL LIFE SCIENCES : New DermaPrecise™ patent application and patents granted fo..
PU
03/22RepliCel Announces Non-brokered Private Placement
AQ
03/21RepliCel Life Sciences Inc. announced that it expects to receive CAD 1.5 million in fun..
CI
2021REPLICEL LIFE SCIENCES : 51-102F3 MATERIAL CHANGE REPORT - Form 6-K
PU
2021REPLICEL LIFE SCIENCES : Closed Final Tranche of Strategic Investment Commitment
PU
2021RepliCel Life Sciences Inc. Terminates License Agreement with Shiseido
CI
2021RepliCel Life Sciences Inc. announced that it has received CAD 0.99892 million in fundi..
CI
2021RepliCel Life Sciences Inc. announced that it expects to receive CAD 0.99892 million in..
CI
2021RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Mon..
CI
More news
Financials
Sales 2020 0,35 M 0,27 M 0,27 M
Net income 2020 -1,58 M -1,22 M -1,22 M
Net Debt 2020 0,54 M 0,42 M 0,42 M
P/E ratio 2020 -2,90x
Yield 2020 -
Capitalization 5,75 M 4,45 M 4,45 M
EV / Sales 2019 25,8x
EV / Sales 2020 22,0x
Nbr of Employees 1
Free-Float 49,9%
Chart REPLICEL LIFE SCIENCES INC.
Duration : Period :
RepliCel Life Sciences Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Robert Lee Buckler President, CEO, Secretary & Director
Simon S. Ma Chief Financial Officer & Finance Director
David M. Hall Chairman
Rolf Hoffmann Chief Medical Officer
Kevin McElwee Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
REPLICEL LIFE SCIENCES INC.-47.49%4
GILEAD SCIENCES, INC.-14.28%78 068
REGENERON PHARMACEUTICALS, INC.3.72%70 575
VERTEX PHARMACEUTICALS15.74%65 005
WUXI APPTEC CO., LTD.-16.20%42 275
BIONTECH SE-41.35%36 745